- Home
- OKLO vs VRNA Comparison
OKLO vs VRNA Comparison
Compare OKLO & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKLO
- VRNA
- Stock Information
- Founded
- OKLO 2013
- VRNA 2005
- Country
- OKLO United States
- VRNA United Kingdom
- Employees
- OKLO 113
- VRNA N/A
- Industry
- OKLO
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- OKLO
- VRNA Health Care
- Exchange
- OKLO NYSE
- VRNA Nasdaq
- Market Cap
- OKLO 9.4B
- VRNA 7.8B
- IPO Year
- OKLO N/A
- VRNA 2017
- Fundamental
- Price
- OKLO $57.99
- VRNA $92.20
- Analyst Decision
- OKLO Strong Buy
- VRNA Strong Buy
- Analyst Count
- OKLO 9
- VRNA 7
- Target Price
- OKLO $58.14
- VRNA $97.57
- AVG Volume (30 Days)
- OKLO 28.2M
- VRNA 1.4M
- Earning Date
- OKLO 08-12-2025
- VRNA 08-07-2025
- Dividend Yield
- OKLO N/A
- VRNA N/A
- EPS Growth
- OKLO N/A
- VRNA N/A
- EPS
- OKLO N/A
- VRNA N/A
- Revenue
- OKLO N/A
- VRNA $118,535,000.00
- Revenue This Year
- OKLO N/A
- VRNA $891.79
- Revenue Next Year
- OKLO N/A
- VRNA $78.94
- P/E Ratio
- OKLO N/A
- VRNA N/A
- Revenue Growth
- OKLO N/A
- VRNA N/A
- 52 Week Low
- OKLO $5.35
- VRNA $14.14
- 52 Week High
- OKLO $73.55
- VRNA $94.45
- Technical
- Relative Strength Index (RSI)
- OKLO 59.37
- VRNA 78.05
- Support Level
- OKLO $60.60
- VRNA $82.18
- Resistance Level
- OKLO $73.55
- VRNA $93.74
- Average True Range (ATR)
- OKLO 6.73
- VRNA 3.21
- MACD
- OKLO -0.20
- VRNA 0.89
- Stochastic Oscillator
- OKLO 45.40
- VRNA 92.52
About OKLO OKLO INC
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.